Marks Group Wealth Management Inc Has $3.40 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Marks Group Wealth Management Inc lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 43,672 shares of the company’s stock after selling 686 shares during the quarter. Marks Group Wealth Management Inc’s holdings in AstraZeneca were worth $3,402,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Pittenger & Anderson Inc. lifted its stake in AstraZeneca by 14.1% in the third quarter. Pittenger & Anderson Inc. now owns 53,377 shares of the company’s stock valued at $4,159,000 after buying an additional 6,590 shares in the last quarter. Martin Investment Management LLC raised its holdings in shares of AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after acquiring an additional 7,615 shares during the period. FSM Wealth Advisors LLC boosted its stake in AstraZeneca by 3.2% in the 3rd quarter. FSM Wealth Advisors LLC now owns 6,138 shares of the company’s stock worth $478,000 after purchasing an additional 188 shares during the period. Catalyst Capital Advisors LLC boosted its stake in AstraZeneca by 6,387.3% in the 3rd quarter. Catalyst Capital Advisors LLC now owns 36,199 shares of the company’s stock worth $2,820,000 after purchasing an additional 35,641 shares during the period. Finally, QRG Capital Management Inc. increased its holdings in AstraZeneca by 12.1% during the 3rd quarter. QRG Capital Management Inc. now owns 223,245 shares of the company’s stock worth $17,393,000 after purchasing an additional 24,114 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent research reports. TD Cowen upped their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Down 7.2 %

NASDAQ AZN opened at $66.27 on Wednesday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a 50 day moving average of $78.87 and a 200-day moving average of $78.77. The company has a market cap of $205.48 billion, a PE ratio of 32.01, a PEG ratio of 1.32 and a beta of 0.47.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.